NCT05313672

Brief Summary

Idiopathic pulmonary fibrosis is a life-threatening lung disease characterized by progressive deterioration of lung function and a median survival time of 3-5 years from diagnosis. The onset of an acute deterioration (AE) of respiratory function, the so called acute exacerbation of IPF (AE-IPF), may lead to severe hypoxemia, further worsening prognosis. During these events, the typical usual interstitial pneumonia pattern (UIP) - the radiologic and histologic hallmark of IPF- is overlapped with diffuse alveolar damage (DAD), sharing similarities with the acute respiratory distress syndrome (ARDS) and often requiring respiratory assistance. Several studies show that the need for mechanical ventilation (MV) is associated with high mortality in IPF patients, probably due to the pathophysiological properties of UIP-like fibrotic lung (i.e. collapse induration areas, elevated lung elastance, high inhomogeneity) that make it more susceptible to ventilatory-induced lung injury (VILI). It has been theorized that the application of PEEP on a UIP-like lung pattern can determine the protrusion of the most distensible areas through a dense anelastic fibrotic tissue circles, causing increased rigidity, worsening compliance, and thus enabling tissue breakdown. In this scenario, non-invasive mechanical ventilation (NIV) may therefore represent an alternative option to assist these patients, although no specific recommendations have been made so far. In patients with ARDS, the efficacy of NIV in reducing the patient's inspiratory effort early after its application has been related to a favorable clinical outcome. Indeed, the mitigation of respiratory drive might have resulted in a lower risk for the self-inflicted lung injury (SILI) during spontaneous breathing, whose onset is very likely to worse outcomes of patients undergoing acute respiratory failure (ARF). To date no data available on the inspiratory effort and the lung mechanics in patients with AE-IPF either during unassisted of assisted spontaneous breathing. Aim of this study was then to compare respiratory mechanics, at baseline and 2-h following NIV application, in AE-IPF and ARDS patients matched for severity.

Trial Health

83
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
3mo left

Started Aug 2016

Longer than P75 for all trials

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress98%
Aug 2016Aug 2026

Study Start

First participant enrolled

August 1, 2016

Completed
5.7 years until next milestone

First Submitted

Initial submission to the registry

March 28, 2022

Completed
4 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 6, 2022

Completed
4.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Expected
Last Updated

April 25, 2025

Status Verified

April 1, 2025

Enrollment Period

5.7 years

First QC Date

March 28, 2022

Last Update Submit

April 24, 2025

Conditions

Keywords

Inspiratory effortEsophageal manometryNon-invasive mechanical ventilation

Outcome Measures

Primary Outcomes (1)

  • Inspiratory effort in IPF patients

    Assessment of esophageal pressure swing in IPF patients during acute exacerbation of disease as compared to ARDS

    On respiratory intensive care unit admission

Secondary Outcomes (1)

  • Respiratory mechanics change after NIV application in IPF patients acute exacerbation

    2 hours

Study Arms (2)

IPF patients with UIP pattern requiring NIV

ARDS patients requiring NIV

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with IPF developing AE consecutively admitted to the Respiratory Intensive Care Unit and the Intensive Care Unit of the University Hospital of Modena over the period August 1st, 2016 to January 1th, 2022 were prospectively considered eligible for enrollment.

You may qualify if:

  • previously established diagnosis of IPF; occurring acute exacerbation of IPF as defined by an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality on chest CT scan (12); age \>18 years; presence of ARF with PaO2/FiO2 ratio \<200 mmHg despite HFNC (set with at least 60 L/min and FiO2 higher than 0.6); suitability for a NIV trial according to the attending staff; consent to measure esophageal pressure.

You may not qualify if:

  • acute cardiogenic pulmonary edema,
  • concomitant hypercapnic respiratory failure (PaCO2 \>45 mmHg) of any etiology,
  • neuromuscular disease or chest wall deformities,
  • home long-term oxygen therapy,
  • intolerance or contraindication to NIV, such as the need for immediate endotracheal intubation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Idiopathic Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Pulmonary FibrosisLung Diseases, InterstitialLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

March 28, 2022

First Posted

April 6, 2022

Study Start

August 1, 2016

Primary Completion

April 1, 2022

Study Completion (Estimated)

August 1, 2026

Last Updated

April 25, 2025

Record last verified: 2025-04